Asked by: Stephen Kinnock (Labour - Aberafan Maesteg)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) increase capacity and (b) improve infrastructure in the NHS to help tackle dementia.
Answered by Helen Whately - Shadow Secretary of State for Work and Pensions
In 2019 we committed to doubling funding for dementia research, to £160 million per year by 2024/25. This will span all areas of research from causes and prevention to treatment and care, delivering evidence to help prevent, diagnose and treat dementia, enabling the best possible care and quality of life for people with dementia.
NHS England are assessing the additional scanning, treating and monitoring capacity which would be required if potential new Alzheimer’s treatments are approved and determined to be both cost and clinically effective. This includes securing additional diagnostic capacity, for instance through magnetic resonance imaging, lumbar puncture, and positron emission tomography and computed tomography.
Asked by: Stephen Kinnock (Labour - Aberafan Maesteg)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will create a long-term strategy to help people with ADHD to access medication they need.
Answered by Maria Caulfield
The Department has no current plans to create a long-term strategy specifically for access to attention deficit hyperactivity disorder (ADHD) medication, nor for raising awareness of ADHD or preventing misdiagnosis of ADHD in women and young girls.
It is the responsibility of local commissioners to make appropriate provisions available to meet the health and care needs of their local population. With respect to assessment, diagnosis and treatment for ADHD, integrated care boards, NHS trusts and health professionals should have due regard to the National Institute for Health and Care Excellence (NICE) guideline, NG87: Attention deficit hyperactivity disorder: diagnosis and management.
This guideline aims to improve recognition and diagnosis of ADHD, specifically highlighting the importance of recognising ADHD in women and girls, and to improve the quality of care and support that people of all ages who are diagnosed with ADHD receive.
The Women’s Health Strategy for England sets out our plans for boosting health outcomes for women and girls and improving how the health and care system listens to women. Improving information provision for women and girls is a priority. In July 2023, we launched a women’s health area on the National Health Service website. This brings together over 100 topics, including ADHD, and our ambition is for the NHS website to be the first port of call for women and girls seeking information.
The NICE guideline also covers considerations on pharmacological and non-pharmacological treatments for ADHD. The guideline states that for children aged five years old and over and for adults, medication should be offered if ADHD symptoms are still causing a significant impairment in at least one domain, after environmental modifications have been implemented and reviewed. Overall, the decision and timescale for initiating medication should be a clinical decision based on the individual patient.
We are aware of current disruptions to the supply of medicines used for the management of ADHD. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to some other medicines which should be largely resolved by April 2024.
Asked by: Stephen Kinnock (Labour - Aberafan Maesteg)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will create a long-term strategy for raising awareness of ADHD in women and young girls.
Answered by Maria Caulfield
The Department has no current plans to create a long-term strategy specifically for access to attention deficit hyperactivity disorder (ADHD) medication, nor for raising awareness of ADHD or preventing misdiagnosis of ADHD in women and young girls.
It is the responsibility of local commissioners to make appropriate provisions available to meet the health and care needs of their local population. With respect to assessment, diagnosis and treatment for ADHD, integrated care boards, NHS trusts and health professionals should have due regard to the National Institute for Health and Care Excellence (NICE) guideline, NG87: Attention deficit hyperactivity disorder: diagnosis and management.
This guideline aims to improve recognition and diagnosis of ADHD, specifically highlighting the importance of recognising ADHD in women and girls, and to improve the quality of care and support that people of all ages who are diagnosed with ADHD receive.
The Women’s Health Strategy for England sets out our plans for boosting health outcomes for women and girls and improving how the health and care system listens to women. Improving information provision for women and girls is a priority. In July 2023, we launched a women’s health area on the National Health Service website. This brings together over 100 topics, including ADHD, and our ambition is for the NHS website to be the first port of call for women and girls seeking information.
The NICE guideline also covers considerations on pharmacological and non-pharmacological treatments for ADHD. The guideline states that for children aged five years old and over and for adults, medication should be offered if ADHD symptoms are still causing a significant impairment in at least one domain, after environmental modifications have been implemented and reviewed. Overall, the decision and timescale for initiating medication should be a clinical decision based on the individual patient.
We are aware of current disruptions to the supply of medicines used for the management of ADHD. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to some other medicines which should be largely resolved by April 2024.
Asked by: Stephen Kinnock (Labour - Aberafan Maesteg)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will create a long-term strategy to help prevent misdiagnosis of ADHD amongst women and young girls.
Answered by Maria Caulfield
The Department has no current plans to create a long-term strategy specifically for access to attention deficit hyperactivity disorder (ADHD) medication, nor for raising awareness of ADHD or preventing misdiagnosis of ADHD in women and young girls.
It is the responsibility of local commissioners to make appropriate provisions available to meet the health and care needs of their local population. With respect to assessment, diagnosis and treatment for ADHD, integrated care boards, NHS trusts and health professionals should have due regard to the National Institute for Health and Care Excellence (NICE) guideline, NG87: Attention deficit hyperactivity disorder: diagnosis and management.
This guideline aims to improve recognition and diagnosis of ADHD, specifically highlighting the importance of recognising ADHD in women and girls, and to improve the quality of care and support that people of all ages who are diagnosed with ADHD receive.
The Women’s Health Strategy for England sets out our plans for boosting health outcomes for women and girls and improving how the health and care system listens to women. Improving information provision for women and girls is a priority. In July 2023, we launched a women’s health area on the National Health Service website. This brings together over 100 topics, including ADHD, and our ambition is for the NHS website to be the first port of call for women and girls seeking information.
The NICE guideline also covers considerations on pharmacological and non-pharmacological treatments for ADHD. The guideline states that for children aged five years old and over and for adults, medication should be offered if ADHD symptoms are still causing a significant impairment in at least one domain, after environmental modifications have been implemented and reviewed. Overall, the decision and timescale for initiating medication should be a clinical decision based on the individual patient.
We are aware of current disruptions to the supply of medicines used for the management of ADHD. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to some other medicines which should be largely resolved by April 2024.
Asked by: Stephen Kinnock (Labour - Aberafan Maesteg)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will create a long-term strategy to ensure supply of key medication for ADHD.
Answered by Andrew Stephenson
Disruptions to the supply of medicines used for the management of attention deficit and hyperactivity disorder (ADHD) have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers, and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, which should be largely resolved by April 2024. We have also added ADHD products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom, to protect supplies for UK patients. We understand how frustrating and distressing medicine supply issues can be and want to assure you that we are working with the respective manufacturers to resolve the issues with ADHD medicine supply in the UK as soon as possible, and to help ensure patients are able to access these medicines in the short and long term.
While we cannot always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise and help mitigate risks to patients. There is a team within the Department that deals specifically with medicine supply problems and which works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, devolved administrations, and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.